Zevra Therapeutics (ZVRA) to Release Quarterly Earnings on Tuesday

Zevra Therapeutics (NASDAQ:ZVRA) will release its earnings data after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The company had revenue of $4.45 million during the quarter, compared to analyst estimates of $4.08 million. Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. During the same period in the previous year, the company posted ($0.15) EPS. On average, analysts expect Zevra Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zevra Therapeutics Price Performance

Shares of ZVRA opened at $9.00 on Monday. The company’s fifty day simple moving average is $7.89 and its 200 day simple moving average is $6.36. Zevra Therapeutics has a 1-year low of $3.89 and a 1-year high of $9.04. The company has a market cap of $473.56 million, a price-to-earnings ratio of -5.36 and a beta of 1.93. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 1.80.

Analysts Set New Price Targets

ZVRA has been the subject of a number of research analyst reports. JMP Securities started coverage on Zevra Therapeutics in a report on Tuesday, September 24th. They set an “outperform” rating and a $17.00 price target for the company. Canaccord Genuity Group dropped their price target on Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research note on Wednesday, September 18th. Maxim Group raised their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zevra Therapeutics in a report on Friday, October 11th. Finally, William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $20.83.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.